GermanyGermany

Biotechnica: Getting smaller and more international

11.10.2010

Hanover - From October 5-7 the Biotechnica in Hanover attracted 9.500 visitors and 500 enterprises. This is the smallest edition for years. "In view of framework conditions currently affecting the biotech industry, this is a solid outcome indeed," reported Stephan Kühne. Indeed in 2008 and 2009 some 11.000 visitors turned up and the number of exhibitors in 2010 declined at a rate of 20% respectively compared with 2009. Whether there will be a Biotechnica 2012 is not yet decided. Before 2008, Biotechnica was staged every two years, starting in 1985. Some companies still cling to the old rhythm and therefore only show up in uneven years, making the even years like 2010 weaker editions. Kühne didn't say if the Deutsche Messe AG will uphold the yearly editions. "We proceed step by step", he said on the final press conference on Thursday, October 7th. Kühne wants to sharpen the profile of the event. One tool for this purpose is the conference program, which will be extended in 2011. 2010 the show's conferences, forums and workshops drew attendance by over 3,000. This year's range of topics extended from biomedicine and
bioinformatics to the food markets of the future. Even if it's getting smaller, Biotechnica is getting more international. Around 25 percent of visitors came from abroad - five percent more than the previous year. Attendance was up from Europe, above all from the United Kingdom, the Netherlands and France, but also from the United States and Russia. The biggest visitor nations consisted of the United Kingdom, the Netherlands, France, Switzerland and the United States
Carrying a prize purse of EUR 75,000, the EUROPEAN BIOTECHNICA AWARD was presented at the opening event on October 4th. The winner was the Galapagos NV company, based in Mechelen, Belgium. The company specializes in research and development of anti-body and small molecular therapies for the treatment of various diseases such as cancer, diabetes or Alzheimer's. A further 45,000 euros in non-cash prizes went to Galapagos and the other Finalists, Apeiron of Austria and Addex Pharmaceuticals of Switzerland. The non-cash prizes comprise free strategy and investment consultancy services provided by Capgemini Consulting and a media service packages facilitated by the European Biotechnology News.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/biotechnica-getting-smaller-and-more-international.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • 4SC0.94 EUR2.17%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

TOP

  • CYTOS0.28 CHF75.0%
  • EPIGENOMICS5.15 EUR45.9%
  • STRATEC BIOMEDICAL48.50 EUR21.7%

FLOP

  • BIOFRONTERA2.52 EUR-13.1%
  • CO.DON2.51 EUR-8.7%
  • ADDEX3.07 CHF-7.0%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.51 EUR139.0%
  • BB BIOTECH181.25 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.35 EUR-41.4%

No liability assumed, Date: 22.11.2014

Current issue

All issues